Overview

D-serine Augmentation of Neuroplasticity

Status:
Completed
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
Schizophrenia is a major public health problem associated with cognitive deficits, such as short and long term memory, executive functioning, attention and speed of processing that are amongst the strongest predictors of impaired functional outcome. In addition, schizophrenia patients show reduced "plasticity", defined as reduced learning. D-serine is a naturally occurring activator of the N-methyl-d-aspartate-type glutamate receptors (NMDAR) in the brain, and this project will assess the optimal dose of D-serine treatment over three sessions of a program designed to measure auditory plasticity.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborator:
Nathan Kline Institute for Psychiatric Research